About vaxart - VXRT
Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.
VXRT At a Glance
Vaxart, Inc.
170 Harbor Way
South San Francisco, California 94080
| Phone | 1-650-550-3500 | Revenue | 237.26M | |
| Industry | Biotechnology | Net Income | 16.33M | |
| Sector | Health Technology | 2025 Sales Growth | 726.683% | |
| Fiscal Year-end | 12 / 2026 | Employees | 74 | |
| View SEC Filings |
VXRT Valuation
| P/E Current | 9.57 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 4.886 |
| Price to Sales Ratio | 0.336 |
| Price to Book Ratio | 0.949 |
| Price to Cash Flow Ratio | 10.34 |
| Enterprise Value to EBITDA | 1.089 |
| Enterprise Value to Sales | 0.122 |
| Total Debt to Enterprise Value | 0.449 |
VXRT Efficiency
| Revenue/Employee | 3,206,189.189 |
| Income Per Employee | 220,635.135 |
| Receivables Turnover | 4.603 |
| Total Asset Turnover | 1.33 |
VXRT Liquidity
| Current Ratio | 1.569 |
| Quick Ratio | 1.569 |
| Cash Ratio | 0.735 |
VXRT Profitability
| Gross Margin | 96.384 |
| Operating Margin | 7.618 |
| Pretax Margin | 7.082 |
| Net Margin | 6.882 |
| Return on Assets | 9.151 |
| Return on Equity | 22.256 |
| Return on Total Capital | 16.191 |
| Return on Invested Capital | 19.034 |
VXRT Capital Structure
| Total Debt to Total Equity | 14.858 |
| Total Debt to Total Capital | 12.936 |
| Total Debt to Total Assets | 6.849 |
| Long-Term Debt to Equity | 9.893 |
| Long-Term Debt to Total Capital | 8.613 |